Anesthesia and Neurointensive Care, Department of Head and Neck, San Raffaele Scientific Institute, via Olgettina 60, 20132, Milan, Italy.
Neurocrit Care. 2012 Dec;17(3):395-400. doi: 10.1007/s12028-012-9684-2.
There are some intracranial insults which are associated with cardiac abnormalities. Studies of these abnormalities have never been carried out in elective intracranial neurosurgery for the removal of brain tumors. Our prospective study aims at quantifying serum cardiac troponin T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP) before and after elective intracranial neurosurgery for tumor resection in patients with no history of cardiac abnormality.
Pre- and postoperative serum cTnT and NT-proBNP were measured in 108 patients submitted to elective major intracranial surgery for the removal of neoplastic lesions. We tested potentially predictive models for these biomarker serum levels.
cTnT was undetectable both before and after surgery. Median (IQR) basal NT-proBNP was 35 (18-69) pg/mL and 110 (51-191) pg/mL after surgery. In a multiple linear regression model, basal NT-proBNP was predicted by age, gender, BMI, and the presence of "mass effect" (midline shift or effaced perimesencephalic cisterns on preoperative CT scan) (whole model P < 0.0001; R (2) = 0.3502; and Adjusted R (2) = 0.3247). Postoperative NT-proBNP increase was predicted by baseline NT-proBNP level (whole model P < 0.0001; R (2) = 0.5106; and Adjusted R (2) = 0.5052).
An intracranial mass effect is associated with higher NT-proBNP serum levels in patients with a brain neoplasm. Following elective intracranial surgery for brain tumor resection NT-proBNP values increase.
有些颅内损伤与心脏异常有关。在择期颅内神经外科切除脑瘤的手术中,从未对这些异常进行过研究。我们的前瞻性研究旨在定量检测无心脏异常病史的患者在择期颅内神经外科肿瘤切除术前和术后血清中心脏肌钙蛋白 T(cTnT)和 N 端脑利钠肽前体(NT-proBNP)。
对 108 例接受择期颅内大手术切除肿瘤的患者进行术前和术后血清 cTnT 和 NT-proBNP 检测。我们测试了这些生物标志物血清水平的潜在预测模型。
cTnT 在手术前后均无法检测到。基础 NT-proBNP 的中位数(IQR)为 35(18-69)pg/ml,术后为 110(51-191)pg/ml。在多元线性回归模型中,基础 NT-proBNP 可由年龄、性别、BMI 和术前 CT 扫描上存在“占位效应”(中线移位或消失中脑周围脑池)来预测(整体模型 P < 0.0001;R²=0.3502;调整 R²=0.3247)。术后 NT-proBNP 增加可由基线 NT-proBNP 水平预测(整体模型 P < 0.0001;R²=0.5106;调整 R²=0.5052)。
颅内占位效应与脑肿瘤患者较高的 NT-proBNP 血清水平相关。择期颅内肿瘤切除术患者术后 NT-proBNP 值增加。